vs
Prestige Consumer Healthcare Inc.（PBH）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是BRC Group Holdings, Inc.的1.5倍（$283.4M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 16.5%，领先31.5%），Prestige Consumer Healthcare Inc.同比增速更快（-2.4% vs -21.9%），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -15.4%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
PBH vs RILY — 直观对比
营收规模更大
PBH
是对方的1.5倍
$188.3M
营收增速更快
PBH
高出19.5%
-21.9%
净利率更高
RILY
高出31.5%
16.5%
两年增速更快
PBH
近两年复合增速
-15.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $188.3M |
| 净利润 | $46.7M | $90.3M |
| 毛利率 | 55.5% | 79.5% |
| 营业利润率 | 29.1% | 32.3% |
| 净利率 | 16.5% | 47.9% |
| 营收同比 | -2.4% | -21.9% |
| 净利润同比 | -23.5% | 1710.8% |
| 每股收益（稀释后） | $0.97 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBHRILY
| Q4 25 | $283.4M | $188.3M | ||
| Q3 25 | $274.1M | $215.3M | ||
| Q2 25 | $249.5M | $188.2M | ||
| Q1 25 | $296.5M | $197.2M | ||
| Q4 24 | $290.3M | $241.0M | ||
| Q3 24 | $283.8M | $225.5M | ||
| Q2 24 | $267.1M | $256.0M | ||
| Q1 24 | $277.0M | $263.4M |
净利润PBHRILY
| Q4 25 | $46.7M | $90.3M | ||
| Q3 25 | $42.2M | $91.1M | ||
| Q2 25 | $47.5M | $139.5M | ||
| Q1 25 | $50.1M | $-10.0M | ||
| Q4 24 | $61.0M | $-5.6M | ||
| Q3 24 | $54.4M | $-284.4M | ||
| Q2 24 | $49.1M | $-433.6M | ||
| Q1 24 | $49.5M | $-49.2M |
毛利率PBHRILY
| Q4 25 | 55.5% | 79.5% | ||
| Q3 25 | 55.3% | 83.7% | ||
| Q2 25 | 56.2% | 81.3% | ||
| Q1 25 | 57.3% | 81.4% | ||
| Q4 24 | 55.5% | 79.8% | ||
| Q3 24 | 55.5% | 82.1% | ||
| Q2 24 | 54.7% | 84.5% | ||
| Q1 24 | 54.8% | 85.3% |
营业利润率PBHRILY
| Q4 25 | 29.1% | 32.3% | ||
| Q3 25 | 29.1% | 30.4% | ||
| Q2 25 | 28.8% | 5.7% | ||
| Q1 25 | 29.8% | -31.2% | ||
| Q4 24 | 31.7% | -69.2% | ||
| Q3 24 | 29.7% | -36.4% | ||
| Q2 24 | 27.0% | -90.8% | ||
| Q1 24 | 29.7% | -6.1% |
净利率PBHRILY
| Q4 25 | 16.5% | 47.9% | ||
| Q3 25 | 15.4% | 42.3% | ||
| Q2 25 | 19.0% | 74.1% | ||
| Q1 25 | 16.9% | -5.1% | ||
| Q4 24 | 21.0% | -2.3% | ||
| Q3 24 | 19.2% | -126.1% | ||
| Q2 24 | 18.4% | -169.4% | ||
| Q1 24 | 17.9% | -18.7% |
每股收益（稀释后）PBHRILY
| Q4 25 | $0.97 | $2.78 | ||
| Q3 25 | $0.86 | $2.91 | ||
| Q2 25 | $0.95 | $4.50 | ||
| Q1 25 | $1.00 | $-0.39 | ||
| Q4 24 | $1.22 | $-0.01 | ||
| Q3 24 | $1.09 | $-9.39 | ||
| Q2 24 | $0.98 | $-14.35 | ||
| Q1 24 | $0.98 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $226.6M |
| 总债务越低越好 | $1.0B | $1.4B |
| 股东权益账面价值 | $1.8B | $-171.5M |
| 总资产 | $3.5B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
现金及短期投资PBHRILY
| Q4 25 | $62.4M | $226.6M | ||
| Q3 25 | $119.1M | $184.2M | ||
| Q2 25 | $139.5M | $267.4M | ||
| Q1 25 | $97.9M | $138.3M | ||
| Q4 24 | $50.9M | $146.9M | ||
| Q3 24 | $51.5M | $159.2M | ||
| Q2 24 | $34.3M | $236.9M | ||
| Q1 24 | $46.5M | $190.7M |
总债务PBHRILY
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $993.1M | $1.3B | ||
| Q2 25 | $992.7M | $1.3B | ||
| Q1 25 | $992.4M | $1.4B | ||
| Q4 24 | $992.0M | $1.5B | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
股东权益PBHRILY
| Q4 25 | $1.8B | $-171.5M | ||
| Q3 25 | $1.8B | $-260.5M | ||
| Q2 25 | $1.9B | $-351.7M | ||
| Q1 25 | $1.8B | $-496.8M | ||
| Q4 24 | $1.8B | $-488.2M | ||
| Q3 24 | $1.7B | $-497.6M | ||
| Q2 24 | $1.7B | $-218.3M | ||
| Q1 24 | $1.7B | $228.4M |
总资产PBHRILY
| Q4 25 | $3.5B | $1.7B | ||
| Q3 25 | $3.4B | $1.7B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.5B | ||
| Q4 24 | $3.3B | $1.8B | ||
| Q3 24 | $3.3B | $2.2B | ||
| Q2 24 | $3.3B | $3.2B | ||
| Q1 24 | $3.3B | $5.0B |
负债/权益比PBHRILY
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 1.68× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $267.2M | — |
8季度趋势，按日历期对齐
经营现金流PBHRILY
| Q4 25 | $78.3M | $26.2M | ||
| Q3 25 | $57.5M | $-60.6M | ||
| Q2 25 | $79.0M | $-25.6M | ||
| Q1 25 | $61.8M | $184.0K | ||
| Q4 24 | $65.1M | $-2.7M | ||
| Q3 24 | $69.8M | $19.5M | ||
| Q2 24 | $54.8M | $111.5M | ||
| Q1 24 | $66.9M | $135.4M |
自由现金流PBHRILY
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $53.6M | — | ||
| Q1 24 | $63.8M | — |
自由现金流率PBHRILY
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 23.0% | — |
资本支出强度PBHRILY
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.1% | — |
现金转化率PBHRILY
| Q4 25 | 1.68× | 0.29× | ||
| Q3 25 | 1.36× | -0.66× | ||
| Q2 25 | 1.66× | -0.18× | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
